Skip to main content
Vaxcell-Bio Therapeutics logo

Vaxcell-Bio Therapeutics — Investor Relations & Filings

Ticker · 323990 ISIN · KR7323990002 KO Manufacturing
Open in API
Filings indexed 228 across all filing types
Latest filing 2025-02-21 Proxy Solicitation & In…
Country KR South Korea
Listing KO 323990

About Vaxcell-Bio Therapeutics

https://vaxcell-bio.com/en/

Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of innovative immunotherapies. The company's primary focus is on oncology, developing a pipeline of cell-based and protein-based treatments, including immune cell therapies and targeted protein-degrading therapeutics. In addition to its core focus on cancer, Vaxcell-Bio is expanding its research into other areas, such as developing drug delivery system (DDS)-based therapies for conditions like macular degeneration.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a 'General Meeting of Shareholders' (주주총회소집결의) for the company Vaxcell-Bio. It details the agenda items, including the approval of financial statements, election of directors and auditors, and amendments to business purposes. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of the meeting's agenda and to request their participation/votes.
2025-02-21 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Amendment Report). It details the granting of stock options to employees/executives, including the number of shares, exercise price, and conditions. In the context of financial filings, stock option grants and their amendments are typically categorized under 'Regulatory Filings' (RNS) as they represent specific corporate disclosures that do not fit into categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes).
2025-02-18 Korean
주식매수선택권부여에관한신고
Remuneration Information Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. Since this is a specific regulatory disclosure regarding capital/equity-related instruments that does not fit into the other specific categories like 'Share Issue' (SHA) or 'Director's Dealing' (DIRS), it is classified as a Regulatory Filing (RNS).
2025-02-18 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Vaxcell-Bio. It details the date, location, and agenda items (such as financial statement approval, director/auditor appointments, and business purpose changes) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2025-02-18 Korean
기타경영사항(자율공시) ( 소규모합병 승인 이사회 결의(주주총회 갈음) 결과보고)
AGM Information Classification · 1% confidence The document is a regulatory filing from Vaxcell-Bio regarding the approval of a small-scale merger with AL Biotech. It details the board resolution results, merger ratios, and the legal basis for the merger under the Commercial Act. Since this document specifically details a merger transaction and its approval status, it falls under M&A activity.
2025-02-18 Korean
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a regulatory filing in South Korea used to disclose significant changes in share ownership (often referred to as the 5% rule or major shareholding notification). The document explicitly states it is a '정정신고' (Correction Report) regarding a previously submitted major shareholding report. This falls under the 'Major Shareholding Notification' category.
2025-02-05 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.